(19)
(11) EP 3 126 383 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.02.2019 Bulletin 2019/09

(45) Mention of the grant of the patent:
19.12.2018 Bulletin 2018/51

(21) Application number: 15718304.7

(22) Date of filing: 02.04.2015
(51) International Patent Classification (IPC): 
C07K 16/00(2006.01)
(86) International application number:
PCT/US2015/024149
(87) International publication number:
WO 2015/153912 (08.10.2015 Gazette 2015/40)

(54)

MODIFIED J-CHAIN

MODIFIZIERTE J-KETTE

CHAÎNE J MODIFIÉE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 03.04.2014 US 201461974738 P

(43) Date of publication of application:
08.02.2017 Bulletin 2017/06

(60) Divisional application:
18212426.3

(73) Proprietor: IGM Biosciences, Inc.
Mountain View, CA 94043 (US)

(72) Inventors:
  • KEYT, Bruce
    Hillsborough, CA 94010 (US)
  • PRESTA, Leonard, George
    San Francisco, CA 94109 (US)
  • ZHANG, Fen
    San Francisco, CA 94127 (US)
  • BALIGA, Ramesh
    Redwood City California 94062 (US)

(74) Representative: Mewburn Ellis LLP 
City Tower 40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB)


(56) References cited: : 
WO-A1-98/30592
 US-A1- 2003 224 443
   
  • LIU XIAN-HUA ET AL: "[Expression of alpha-defensin-1 with J chain in the transfected COS-7 cells].", ZHONGGUO WEI ZHONG BING JI JIU YI XUE = CHINESE CRITICAL CARE MEDICINE = ZHONGGUO WEIZHONGBING JIJIUYIXUE FEB 2006, vol. 18, no. 2, February 2006 (2006-02), pages 71-73, XP002743330, ISSN: 1003-0603
  • J SYMERSKY ET AL: "Expression of the recombinant human immunoglobulin J chain in Escherichia coli", MOLECULAR IMMUNOLOGY, vol. 37, no. 3-4, 1 February 2000 (2000-02-01), pages 133-140, XP55207594, ISSN: 0161-5890, DOI: 10.1016/S0161-5890(00)00035-3
  • FOURNIER PHILIPPE ET AL: "Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future", BIODRUGS: CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY, ADIS INTERNATIONAL, FR, vol. 27, no. 1, 1 February 2013 (2013-02-01), pages 35-53, XP009178816, ISSN: 1173-8804, DOI: 10.1007/S40259-012-0008-Z
  • RAJU T SHANTHA ET AL: "Potential therapeutic roles for antibody mixtures", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 13, no. 10, 1 October 2013 (2013-10-01), pages 1347-1352, XP009179416, ISSN: 1744-7682
  • SUMIT GOSWAMI ET AL: "Developments and Challenges for mAb-Based Therapeutics", ANTIBODIES, vol. 2, no. 3, 16 August 2013 (2013-08-16) , pages 452-500, XP055128980, DOI: 10.3390/antib2030452
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).